Document Type : Case Report
Authors
Rheumatology and Immunology department, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China.
Abstract
Macrophage activation syndrome (MAS), a secondary hemophagocytic lymphohistiocytosis characterized by an excessive systemic inflammatory response, is a life-threatening and rare disease. Cardiovascular damage is a common and severe complication of the disease, however, it is easily ignored and not well studied. Herein, we report two cases of patients with MAS-associated heart damage and review the clinical characteristics, mechanism, and treatment. Case 1 along with systemic lupus erythematosus and Kikuchi necrotizing lymphadenitis occurred in fatal acute heart failure, and case 2 complicated adult-onset Still’s Disease began with atrial fibrillation and had some improvement with the treatment of high dose corticosteroids. MAS-associated heart damage is a critical issue in clinical settings, and the etiology and mechanisms of MAS-associated cardiovascular diseases are likely multifactorial. The manifestations were various and high levels of the cytokines and cardiac damage may contribute to poor prognosis. Therefore, early intensive immunosuppressive therapy probably improves the treatment outcome.
Keywords
- Paul LaRose ́e, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Jun 6;133(23):2465-2477.
- Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119.
- Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145-59. doi: 10.1146/annurev-med-061813-012806.
- Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014 Nov;66(11):3160-9. doi: 10.1002/art.38802.
- Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS, Xiao JH, Yu HG, Guo L, Xu YP, Lu MP. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China. World J Pediatr. 2020 Feb;16(1):89-98. doi: 10.1007/s12519-019-00256-0.
- Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr. 2011 Dec;63(6):459-66.
- Gavand PE, Serio I, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017 Jul;16(7):743-749. doi: 10.1016/j.autrev.2017.05.010.
- Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503-1516. doi: 10.1016/S0140-6736(13)61048-X. Epub 2013 Nov 27. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.
- Bae CB, Jung JY, Kim HA, Suh CH. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore). 2015 Jan;94(4):e451. doi: 10.1097/MD.0000000000000451.
- Mostaza-Fernández JL, Guerra Laso J, Carriedo Ule D, Ruiz de Morales JM. Hemophagocytic lymphohistiocytosis associated with viral infections: Diagnostic challenges and therapeutic dilemmas. Linfohistiocitosis hemofagocítica asociada a infecciones virales: reto diagnóstico y dilema terapéutico. Rev Clin Esp (Barc). 2014;214(6):320-327. doi:10.1016/j.rce.2014.03.009
- Tocchetti CG, Cadeddu C, Di Lisi D, et al. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal. 2019;30(18):2110-2153. doi:10.1089/ars.2016.6930
- Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res. 2004 Dec 10;95(12):1140-53. doi: 10.1161/01.RES.0000150734.79804.92.
- Bozkurt D, Bozgul SMK, Emgin O, Butun O, Kose T, Simsek E, Hekimgil M, Kilic S. Mortal Interaction Between Hemophagocytic Syndrome and Newly Developed Heart Failure. Arq Bras Cardiol. 2021 Mar;116(3):395-401. English, Portuguese. doi: 10.36660/abc.20190642.
- Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018 Dec;18(12):733-744. doi: 10.1038/s41577-018-0065-8.
- Peng J, Luo F, Ruan G, Peng R, Li X. Hypertriglyceridemia and atherosclerosis. Lipids Health Dis. 2017 Dec 6;16(1):233. doi: 10.1186/s12944-017-0625-0.
- Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A, Hinschberger O, Mouthon L, Le Guern V, Korganow AS, Poindron V, Gourguechon C, Lavigne C, Maurier F, Labro G, Heymonet M, Artifoni M, Viau AB, Deligny C, Sene T, Terriou L, Sibilia J, Mathian A, Bloch-Queyrat C, Larroche C, Amoura Z, Martin T. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017 Jul;16(7):743-749. doi: 10.1016/j.autrev.2017.05.010.
- Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019 Jan 1;58(1):5-17. doi: 10.1093/rheumatology/key006.
- Di Benedetto P, Cipriani P, Iacono D, Pantano I, Caso F, Emmi G, et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS One. 2020 Jul 9;15(7):e0235326. doi: 10.1371/journal.pone.0235326.
- Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.
- Bozkurt D, Bozgul SMK, Emgin O, Butun O, Kose T, Simsek E, Hekimgil M, Kilic S. Mortal Interaction Between Hemophagocytic Syndrome and Newly Developed Heart Failure. Arq Bras Cardiol. 2021 Mar;116(3):395-401. English, Portuguese. doi: 10.36660/abc.20190642. PMID: 33909765; PMCID: PMC8159566.
- Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE, et al. Hellenic Sepsis Study Group. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017 Sep 18;15(1):172. doi: 10.1186/s12916-017-0930-5.
- Hanna A, Frangogiannis NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther. 2020;34(6):849-863. doi:10.1007/s10557-020-07071-0
- Harano Y, Ishikawa Y, Hattori K, Ichinose M, Tomofuji Y, Okano H, et al. A case of complete atrioventricular block in secondary hemophagocytic syndrome/hemophagocytic lymphohistiocytosis recovered by plasma exchange and cytokine absorbing therapy with AN69ST continuous hemodiafiltration. Immunol Med. 2020 Dec;43(4):171-178. doi: 10.1080/25785826.2020.1761145. Epub 2020 May 6. PMID: 32374660.
)